Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Coteur

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Validity And Responsiveness Of The Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) In A Randomized Controlled Clinical TrialJ Kirwan, G Coteur, E Dures, et al.
Marine Pollution Bulletin|August 30, 2001
Effects of PCBs on reactive oxygen species (ROS) production by the immune cells of Paracentrotus lividus (Echinodermata)G Coteur, B Danis, S W Fowler, et al.
Arthritis Care & Research|April 3, 2015
Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial SpondyloarthritisJ Sieper, A Kivitz, A van Tubergen, et al.
Archives of Environmental Contamination and Toxicology|October 21, 2003
Echinoderms as bioindicators, bioassays, and impact assessment tools of sediment-associated metals and PCBs in the North SeaG Coteur, P Gosselin, P Wantier, et al.
The British Journal of Dermatology|March 15, 2012
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extensionK Reich, J-P Ortonne, A B Gottlieb, et al.
The Science of the Total Environment|August 2, 2005
Bioaccumulation and effects of PCBs and heavy metals in sea stars (Asterias rubens, L.) from the North Sea: a small scale perspectiveB Danis, P Wantier, R Flammang, et al.
Alimentary Pharmacology & Therapeutics|January 13, 2011
Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximabB G Feagan, W J Sandborn, D C Wolf, et al.
Annals of the Rheumatic Diseases|November 19, 2008
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyR Fleischmann, J Vencovsky, R F van Vollenhoven, et al.
Annals of the Rheumatic Diseases|September 10, 2013
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 studyR Landewé, J Braun, A Deodhar, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Validity And Responsiveness Of The Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) In A Randomized Controlled Clinical TrialJ Kirwan, G Coteur, E Dures, et al.
Marine Pollution Bulletin|August 30, 2001
Effects of PCBs on reactive oxygen species (ROS) production by the immune cells of Paracentrotus lividus (Echinodermata)G Coteur, B Danis, S W Fowler, et al.
Arthritis Care & Research|April 3, 2015
Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial SpondyloarthritisJ Sieper, A Kivitz, A van Tubergen, et al.
Archives of Environmental Contamination and Toxicology|October 21, 2003
Echinoderms as bioindicators, bioassays, and impact assessment tools of sediment-associated metals and PCBs in the North SeaG Coteur, P Gosselin, P Wantier, et al.
The British Journal of Dermatology|March 15, 2012
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extensionK Reich, J-P Ortonne, A B Gottlieb, et al.
The Science of the Total Environment|August 2, 2005
Bioaccumulation and effects of PCBs and heavy metals in sea stars (Asterias rubens, L.) from the North Sea: a small scale perspectiveB Danis, P Wantier, R Flammang, et al.
Alimentary Pharmacology & Therapeutics|January 13, 2011
Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximabB G Feagan, W J Sandborn, D C Wolf, et al.
Annals of the Rheumatic Diseases|November 19, 2008
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyR Fleischmann, J Vencovsky, R F van Vollenhoven, et al.
Annals of the Rheumatic Diseases|September 10, 2013
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 studyR Landewé, J Braun, A Deodhar, et al.
Pageof 2